Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles by Lara Hart
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Lara Hart wrote the following 2 articles about Crohn Disease.
 
+ Citations + Abstracts
1 Review Endoscopic scoring systems for the evaluation and monitoring of disease activity in Crohn's disease. 2019

Hart, Lara / Bessissow, Talat. ·Division of Pediatric Gastroenterology, Department of Pediatrics, McMaster University Medical Center (MUMC), McMaster Children's Hospital, 1200 Main St. W, 3A, Hamilton, ON, Canada; Division of Gastroenterology, Department of Medicine, McGill University Health Center (MUHC), Montreal General Hospital, 1650 Cedar Ave, C7-200, Montreal, QC, H3G 1A4, Canada. Electronic address: lara.hart@medportal.ca. · Division of Gastroenterology, Department of Medicine, McGill University Health Center (MUHC), Montreal General Hospital, 1650 Cedar Ave, C7-200, Montreal, QC, H3G 1A4, Canada. Electronic address: talat.bessissow@mcgill.ca. ·Best Pract Res Clin Gastroenterol · Pubmed #31327405.

ABSTRACT: Crohn's disease is a chronic relapsing idiopathic condition that can affect any part of the gastrointestinal tract. It has been shown that mucosal healing is associated with improved clinical outcomes such as reduced risk of surgery, hospitalization and complications. Nowadays mucosal healing is considered the optimal target of medical therapy. To evaluate the mucosa in an objective and standardized manner, it is important to rely on accurate and validated endoscopic scores. The Crohn's disease endoscopic index of severity, the simple endoscopic score for Crohn's disease as well as the Rutgeerts score will be reviewed. Their clinical implications and limitations will be discussed.

2 Article Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study. 2019

Chavannes, Mallory / Martinez-Vinson, Christine / Hart, Lara / Kaniki, Nicole / Chao, Che-Yung / Lawrence, Sally / Jacobson, Kevan / Hugot, Jean-Pierre / Viala, Jérome / Deslandres, Colette / Jantchou, Prevost / Seidman, Ernest G. ·Department of Paediatrics, Sainte-Justine UHC, University of Montreal, QC, Canada. · Department of Paediatrics, Children Hospital of Los Angeles, Los Angeles, CA, USA. · Division of Paediatric Gastroenterology, Hôpital Robert-Debré, Assistance Publique-Hôpitaux de Paris, Paris, France. · Montreal Children's Hospital, Department of Paediatrics, McGill University, Montreal, QC, Canada. · Research Western, Western University, London, ON, Canada. · Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, QLD, Australia. · Division of Paediatric Gastroenterology Hepatology and Nutrition, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada. · UFR de Médecine, Université Paris Diderot-Sorbonne Paris Cité, Paris, France. · Research Centre of CHU Sainte-Justine, University of Montreal, Montreal, QCc, Canada. ·J Crohns Colitis · Pubmed #30541021.

ABSTRACT: BACKGROUND: Ustekinumab [UST] is effective in the treatment of adults with moderate to severe Crohn's disease [CD]. There is a paucity of data on its use in children. AIM: To evaluate the response to UST in children with moderate to severe CD. METHODS: This multicentre retrospective cohort study identified children under 18 years old with CD, who received open-labelled subcutaneous UST. The primary outcome was changes in mean abbreviated Paediatric Crohn's Disease Activity Index [aPCDAI] between baseline and 3 and 12 months, and rate of clinical remission at 3 and 12 months. Secondary outcomes were clinical response at the same time points, changes in C-reactive protein [CRP] and albumin, improvement in growth parameters, and rate of adverse events. RESULTS: A total of 44 patients who failed at least one biological treatment were identified. Linear mixed model [LMM] analysis revealed a statistically significant effect of UST (χ2[1] = 42.7, p = 1.2 × 10-8) which lowered the aPCDAI scores by about 16 ± 2.7 at 3 months, and 19.6 ± 2.9 at 12 months. At 12 months, 38.6% of the patients achieved clinical remission and 47.8% achieved clinical response. There was a significant increase in mean weight z-score of 0.48 [±0.13] [p <0.001] and in mean body mass index [BMI] z score of 0.66 [±0.16] [p <0.001]. The probability of remaining on UST at 12 months was 76.9%. The rate of adverse events was 12.4 per 1000 patient-months. CONCLUSIONS: Subcutaneous UST should be considered a viable therapeutic option for paediatric patients who are refractory to other biological agents. Prospective randomised trials are needed.